> ## Content Index
> Fetch the complete content index at: https://med-techinsights.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Viromed Medical announces partnership with AMAMUS Vet for ViroCap device
- URL: https://med-techinsights.com/viromed-medical-announces-partnership-with-amamus-vet-for-virocap-device/
- Published: 2025-04-14T08:55:53.000Z
- Updated: 2026-10-23T02:47:37.000Z
- Description: Viromed Medical AG, a medical technology company and pioneer of cold plasma technology for applications in wound healing, intensive care medicine and air disinfection, and Lang Life Sciences GmbH, with its brand and veterinary platform AMAMUS Vet have signed an exclusive agreement to market Viromed’
- Author: Oliver Johnson
- Tags: Medical Device Manufacturing, News

[**Viromed Medical AG**](https://www.viromed.de/en/?ref=med-techinsights.com), a medical technology company and pioneer of cold plasma technology for applications in wound healing, intensive care medicine and air disinfection, and **Lang Life Sciences GmbH**, with its brand and veterinary platform [**AMAMUS Vet**](https://www.amamusvet.de/en/?ref=med-techinsights.com) have signed an exclusive agreement to market Viromed’s cold plasma medical device ViroCAP for use in veterinary medicine in Germany, Austria, and Switzerland. 

Lang Life Sciences obtains exclusive rights to distribute ViroCAP VET for the veterinary treatment of skin infections, eczema, allergic skin reactions, bite wounds and other skin diseases in animals. The company will purchase a minimum volume of 1,000 ViroCAP devices over the first 12 months and will market and distribute them under the umbrella brand AMAMUS Vet in the DACH region. Deliveries will begin at the end of August. From this date, AMAMUS Vet will exclusively distribute ViroCAP VET in the cold plasma segment. 

“Our aim is to utilise innovative products to reduce the use of antibiotics in veterinary medicine and to enable the most pain-free therapies possible for animals,” says Jan Lang, founder and Managing Director of Lang Life Sciences GmbH. “This is why we have used cold plasma technology since 2018\. The technology has the properties of a digital antibiotic while also preventing and treating viral infections. In scientific studies, Viromed’s ViroCAP has shown a superior profile in the effective, painless and, in particular, contactless treatment of dermatological diseases. We are very pleased to be able to expand our portfolio with this innovation, which has the potential to reduce millions of doses of antibiotics in veterinary medicine every year.” 

“The partnership with Lang Life Sciences marks Viromed’s entry into veterinary medicine – an important and growing market with around 10,000 veterinary practices and veterinary clinics in Germany alone. We were very impressed by Jan Lang and his team’s many years of experience, high level of expertise and particular passion for animal welfare,” saysUwe Perbandt, CEO of Viromed Medical AG.“By bringing together two pioneers in the development and application of cold plasma medicine, we are able to establish ViroCAP in the veterinary sector through a strong distribution network and provide a particularly effective and animal-friendly treatment option. In addition, the partnership with AMAMUS Vet opens opportunities for us to enter the vast veterinary U.S. market in the future.”